Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:

NCT ID: NCT03476655 Completed - Clinical trials for Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India

Start date: April 28, 2018
Phase:
Study type: Observational

The purpose of this study is to describe the effectiveness (overall response rate [ORR] and time to progression [TPP]) of Ibrutinib therapy in participants with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

NCT ID: NCT03476239 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Start date: October 18, 2017
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the rate of hematological response (complete remission/complete remission with partial hematological recovery [CR/CRh*]) induced by blinatumomab in Chinese adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

NCT ID: NCT03472573 Completed - Clinical trials for Recurrent B Acute Lymphoblastic Leukemia

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Start date: May 9, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of palbociclib when given together with dexamethasone in treating participants with B-cell acute lymphoblastic leukemia that has come back after a period of improvement or does not respond to treatment. Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a steroid medication that is used in combination with other medications to treat B-cell acute lymphoblastic leukemia. Giving palbociclib together with dexamethasone may work better in treating patients with B-cell acute lymphoblastic leukemia.

NCT ID: NCT03471416 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Nutritional Status in Children With ALL in Guatemala

Start date: May 1, 2019
Phase:
Study type: Observational

This study proposes to investigate the association of nutritional status of a children assessed by body mass index (BMI), triceps skinfold thickness (TSFT), and mid upper arm circumference (MUAC), with body composition, measured by dual-energy X-ray absorptiometry (DEXA), in 60 children undergoing treatment of ALL at Unidad Nacional de Oncologia Pediatrica (UNOP), in Guatemala City, Guatemala. The study also aims to establish normative values of body composition in children residing in an LMIC by examining 160 healthy siblings of children under treatment, and to measure habitual physical activity in children with acute lymphoblastic leukemia (ALL) at diagnosis and during therapy.

NCT ID: NCT03469895 Active, not recruiting - Clinical trials for Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia

Autoimmune Cytopenia and BcR Inhibitors

CABRI
Start date: July 21, 2017
Phase:
Study type: Observational

Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)

NCT ID: NCT03467867 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Start date: April 26, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL).

NCT ID: NCT03467256 Active, not recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

Start date: May 14, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficiency of autologous CD19 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia

NCT ID: NCT03462719 Active, not recruiting - Clinical trials for Leukemia, Lymphocytic, Chronic, B-Cell

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

GLOW
Start date: April 17, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).

NCT ID: NCT03462095 Recruiting - Clinical trials for Precursor Cell Lymphoblastic Leukemia-Lymphoma

De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)

Start date: January 2017
Phase: N/A
Study type: Interventional

No high-dose methotrexate (MTX) and high-dose cytarabine (ARA-C) consolidation blocks, L-asparaginaseis scheduled for 1 year of treatment, 21 intrathecal injections through the whole treament, T-ALL patients in complete remossion (CR) after the informed consent are randomized to: auto-HSCT vs no auto-HSCT, - with the similar further maintenance. Stem cell harvest is performed after the 3rd consolidation by G-SCF disregarding minimal residual disease (MRD) level. Auto-HSCT is planned after the 5th consolidation phase. All primary bone samples are collected and tested for cytogenetics and molecular markers, all included patients are monitored by flow cytometry by aberrant immunophenotype in a centralized lab.

NCT ID: NCT03460522 Recruiting - Clinical trials for Precursor Cell Lymphoblastic Leukemia

Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Start date: May 2, 2018
Phase: Phase 2
Study type: Interventional

The trial proposed to evaluate the efficacy and safety of an inotuzumab ozogamicin followed by maintenance treatment in patients with acute lymphoblastic leukemia older than 56 years